Brauchen wir den Oralen Glukose-Toleranz-Test?

Hintergrund: Methoden: Ergebnis: Schlussfolgerung: Background: Methods: Result: Conclusion:

[1]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[2]  E. Ford,et al.  Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. , 2004, Archives of internal medicine.

[3]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[4]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[5]  S. Jacob,et al.  Gesundheitsvorsorge und Diabetes-Früherkennung , 2004 .

[6]  K. Fink,et al.  Screening for type 2 diabetes mellitus in adults. , 2004, American family physician.

[7]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[8]  J. Gerich.  Clinical significance, pathogenesis, and management of postprandial hyperglycemia. , 2003, Archives of internal medicine.

[9]  J. Tuomilehto,et al.  Post-challenge hyperglycaemia is associated with premature death and macrovascular complications , 2003, Diabetologia.

[10]  H. Löwel,et al.  High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000 , 2003, Diabetologia.

[11]  S. Haffner,et al.  Predicting future cardiovascular disease: do we need the oral glucose tolerance test? , 2002, Diabetes care.

[12]  Walter C Willett,et al.  Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. , 2002, Diabetes care.

[13]  S. Haffner,et al.  Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.

[14]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[15]  R. Kronmal,et al.  Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. , 2002, Archives of internal medicine.

[16]  P. H. Petersen,et al.  Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests , 2002, Scandinavian journal of clinical and laboratory investigation.

[17]  B. Balkau,et al.  Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. , 2001, Diabetes care.

[18]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[19]  C. Loria,et al.  Subclinical states of glucose intolerance and risk of death in the U.S. , 2001, Diabetes care.

[20]  N. Wareham,et al.  Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.

[21]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[22]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[23]  P. Savage,et al.  Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria , 1999, The Lancet.

[24]  J. Shaw,et al.  Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality , 1999, Diabetologia.

[25]  K. Yano,et al.  Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. , 1999, Diabetes care.

[26]  T. Welborn,et al.  New classification and criteria for diagnosis of diabetes mellitus , 1999, The Medical journal of Australia.

[27]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[28]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[29]  H. Lithell,et al.  Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data , 1998 .

[30]  E. Barrett-Connor,et al.  Isolated Postchallenge Hyperglycemia and the Risk of Fatal Cardiovascular Disease in Older Women and Men: The Rancho Bernardo Study , 1998, Diabetes Care.

[31]  S. Haffner,et al.  Reversion From Type 2 Diabetes to Nondiabetic Status: Influence of the 1997 American Diabetes Association criteria , 1998, Diabetes Care.

[32]  I. Stratton,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[33]  Beverley Balkau,et al.  High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.

[34]  J. Chan,et al.  The Reproducibility and Usefulness of the Oral Glucose Tolerance Test in Screening for Diabetes and other Cardiovascular Risk Factors , 1998, Annals of clinical biochemistry.

[35]  L. Bouter,et al.  Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study , 1996, Diabetologia.

[36]  M. Laakso,et al.  Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations? , 1995, Diabetologia.

[37]  วิชัย เอกพลากร,et al.  พัฒนาดัชนี Diabetes risk score , 2005 .

[38]  J. Tuomilehto,et al.  Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? , 2003, Diabetes care.

[39]  J. Tuomilehto,et al.  Glucose tolerance and cardiovascular mortality , 2001 .

[40]  L. Bouter,et al.  Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. , 2000, Diabetes care.

[41]  E. Feskens,et al.  Intra- and interindividual variability of glucose tolerance in an elderly population. , 1991, Journal of clinical epidemiology.

[42]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .